About Us
AI BIO DUE DILIGENCE
The company was founded by biotechnology investors and financial executives who have invested in biotechnology startups and been involved in many due diligence projects prior to investing in the company.
Our founders recognized the importance of certain recent major scientific breakthroughs in AI machine learning in predicting protein folding that can identify biotech failures earlier and provide data for more efficient allocation of investment capital. These advantages are now available to our clients.
AI and machine learning in biotechnology has the power to filter and extract value from volumes of raw digital information housed in the world’s largest data banks. These technologies can sort through millions of data points in seconds and deliver complete data coverage far beyond that which individual scientific consultants regardless of title or position, can ever do.
Further, when coupled with any one of dozens of modern “docking software” programs this process can be extremely predictive of the success or failure of an initial hypothesis or target interaction.
Big Pharma has utilized AI decision making in large phase II trials to avoid allocating large amounts capital inappropriately. Until these recent breakthroughs in technology this has been too expensive to utilize for early and mid-stage biotechnology startups.
When working toward an efficient outcome both sides of a deal should be able to get a full assessment of all the potential risks and opportunities. The majority of parties employing biotech due diligence in startup and mid size biotechs are running legacy due diligence procedures. Most often the weakest item in a long check list of due diligence is basic science questions, such as what the underlying technology is and how should a drug candidate interact with the biological pathway. As of last year this question can be answered with AI machine learning programs.
Biotech startups are very different and specific in that their investors usually look to one or two experts in the field who have some experience in that biology system and ask for an “opinion”. AI machine learning has proven that it can far surpass human “experts” even in the field of chess championships.
Because biotechnology products tend to be highly regulated by multiple government agencies and can directly affect patients’ health and well-being, the basic science questions are pivotal items in any due diligence effort decision.Without proper due diligence, latent problems could cause issues at any moment, putting the company and its investors’ funds at risk. AIBio due diligence is poised to change the game entirely.